

JAMA | Original Investigation

Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes

Kasia J. Lipska, MD, MHS; Melissa M. Parker, MS; Howard H. Moffet, MPH; Elbert S. Huang, MD, MPH; Andrew J. Karter, PhD

 Editorial page 38

 Author Audio Interview

IMPORTANCE In clinical trials of patients with type 2 diabetes, long-acting insulin analogs modestly reduced the risk of nocturnal hypoglycemia compared with human neutral protamine Hagedorn (NPH) insulin, but cost 2 to 10 times more. Outcomes in clinical practice may differ from trial results.

OBJECTIVE To compare the rates of hypoglycemia-related emergency department (ED) visits or hospital admissions associated with initiation of long-acting insulin analogs vs human NPH insulin in patients with type 2 diabetes.

DESIGN, SETTING, AND PARTICIPANTS A retrospective observational study using data from Kaiser Permanente of Northern California from January 1, 2006, through September 30, 2015. Patients with type 2 diabetes who initiated a long-acting insulin analog or NPH insulin were included and censored at death, loss of health plan coverage, change in insulin treatment, or study end on September 30, 2015.

EXPOSURE Initiation of basal insulin analogs (glargine or detemir) vs NPH insulin.

MAIN OUTCOMES AND MEASURES The primary outcome was the time to a hypoglycemia-related ED visit or hospital admission and the secondary outcome was the change in hemoglobin A_{1c} level within 1 year of insulin initiation.

RESULTS There were 25 489 patients with type 2 diabetes who initiated basal insulin therapy (mean age, 60.2 [SD, 11.8] years; 51.9% white; 46.8% female). During a mean follow-up of 1.7 years, there were 39 hypoglycemia-related ED visits or hospital admissions among 1928 patients who initiated insulin analogs (11.9 events [95% CI, 8.1 to 15.6] per 1000 person-years) compared with 354 hypoglycemia-related ED visits or hospital admissions among 23 561 patients who initiated NPH insulin (8.8 events [95% CI, 7.9 to 9.8] per 1000 person-years) (between-group difference, 3.1 events [95% CI, -1.5 to 7.7] per 1000 person-years; $P = .07$). Among 4428 patients matched by propensity score, the adjusted hazard ratio was 1.16 (95% CI, 0.71 to 1.78) for hypoglycemia-related ED visits or hospital admissions associated with insulin analog use. Within 1 year of insulin initiation, hemoglobin A_{1c} level decreased from 9.4% (95% CI, 9.3% to 9.5%) to 8.2% (95% CI, 8.1% to 8.2%) after initiation of insulin analogs and from 9.4% (95% CI, 9.3% to 9.5%) to 7.9% (95% CI, 7.9% to 8.0%) after initiation of NPH insulin (adjusted difference-in-differences for glycemic control, -0.22% [95% CI, -0.09% to -0.37%]).

CONCLUSIONS AND RELEVANCE Among patients with type 2 diabetes, initiation of a basal insulin analog compared with NPH insulin was not associated with a reduced risk of hypoglycemia-related ED visits or hospital admissions or with improved glycemic control. These findings suggest that the use of basal insulin analogs in usual practice settings may not be associated with clinical advantages for these outcomes.

Author Affiliations: Section of Endocrinology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut (Lipska); Division of Research, Kaiser Permanente of Northern California, Oakland (Parker, Moffet, Karter); Department of Medicine, University of Chicago, Chicago, Illinois (Huang); Department of General Internal Medicine, University of California, San Francisco (Karter); Department of Epidemiology, University of Washington, Seattle (Karter); Department of Health Services, University of Washington, Seattle (Karter).

Corresponding Author: Kasia J. Lipska, MD, MHS, Yale School of Medicine, PO Box 208020, New Haven, CT 06520 (kasia.lipska@yale.edu).

JAMA. 2018;320(1):53-62. doi:10.1001/jama.2018.7993
Published online June 23, 2018.

Treatment of type 2 diabetes typically begins with lifestyle modification and initiation of metformin; however, 14% to 25% of patients eventually require initiation of insulin to reach recommended glycemic targets.^{1,2} The mainstay of insulin treatment has long been human synthetic insulin; however, insulin analogs have become increasingly popular in clinical practice during the past decade.^{3,4} Insulin analogs are molecularly altered forms of insulin that more closely mimic the pharmacokinetic profile of endogenous insulin.

In clinical trials, long-acting insulin analogs modestly reduce the risk of nocturnal hypoglycemia compared with human insulin, but have not been shown to reduce the risk of severe hypoglycemia or to improve glycemic control among patients with type 2 diabetes.⁵ Discrepancies between trial results and outcomes in clinical practice are common and highlight the importance of gathering additional evidence from usual care settings.⁶

Although human insulin products are still used preferentially within Kaiser Permanente of Northern California (KPNC), prior work demonstrated widespread adoption of insulin analogs among US patients during the past 2 decades.^{3,4,7} At the same time, the prices of insulin analogs have increased dramatically,^{8,9} Medicaid payments for insulin have increased substantially,¹⁰ and patients' out-of-pocket spending on insulin analogs has doubled.⁴ In this setting, it is imperative to understand the differences in health outcomes associated with the use of the more expensive insulin analogs vs the more affordable human insulin products.

This study investigated the rates of hypoglycemia-related emergency department (ED) visits or hospital admissions and changes in levels of glycemic control after initiation of long-acting insulin analogs (glargine or detemir) compared with human neutral protamine Hagedorn (NPH) insulin among patients with type 2 diabetes in clinical practice.

Methods

Study Source

The institutional review boards of the Kaiser Foundation Research Institute and the University of Chicago approved the study. Participant informed consent was waived. A large, integrated health care delivery system, KPNC provides care for approximately 30% of the residents in the Northern California service area. The KPNC diabetes registry has been maintained since 1993. The registry now includes more than 350 000 adults with diabetes and is updated annually by identifying all health plan members with diabetes.

The identification of clinically recognized diabetes among health plan members is based on multiple sources of data including pharmacy use; laboratory results; and outpatient, emergency department, and hospitalization diagnoses of diabetes detailed further in a published algorithm.¹¹ Race/ethnicity was measured because prior studies suggest it is associated with both hypoglycemia and glycemic control.^{12,13} Determination of race/ethnicity was based on self-reported race/ethnicity captured in the electronic

Key Points

Question Is initiation of a basal insulin analog compared with human neutral protamine Hagedorn (NPH) insulin associated with a reduced risk of hypoglycemia-related emergency department (ED) visits or hospital admissions in patients with type 2 diabetes?

Findings In this retrospective observational study of 25 489 patients with type 2 diabetes, initiation of basal insulin analogs compared with NPH insulin was not associated with a significant difference in hypoglycemia-related ED visits or hospital admissions among a propensity-score matched cohort of 4428 patients (hazard ratio, 1.16).

Meaning Among patients with type 2 diabetes, the use of basal insulin analogs compared with NPH insulin was not associated with a reduced risk of hypoglycemia-related ED visits or hospital admissions.

medical record according to fixed categories. The study methods and a validation study of the KPNC diabetes registry (99% sensitivity for diabetes based on chart review registration) have been published.¹⁴

Study Population

Using electronic medical records from KPNC, 49 190 adults (aged ≥ 19 years) with diabetes were identified. Each patient had full health plan and prescription coverage for 24 months prior to initiating insulin between January 1, 2006, and December 31, 2014. Patients with type 1 diabetes were excluded ($n = 1838$) based on a validated algorithm that uses self-report or age of diabetes onset and drug treatment history to determine diabetes type.¹⁵ Clinicians within KPNC can prescribe either NPH insulin or insulin analogs to patients with type 2 diabetes without obtaining prior approval; however, clinicians are encouraged to start with NPH insulin.

The analytic cohort consisted of patients who initiated basal insulin therapy and had no insulin prescription fills during the prior 12 months (Figure 1). Patients started with either NPH insulin or the insulin analog glargine or detemir. Patients using prandial insulin at baseline were excluded from the study. Patients who initiated prandial insulin during the study were censored at that time.

Study Outcomes

The primary outcome was the time to hypoglycemia-related ED visit or hospital admission after initiation of insulin therapy based on a primary or principal discharge diagnosis of hypoglycemia using a validated algorithm (any of the following *International Classification of Diseases, Ninth Revision* codes: 251.0, 251.1, 251.2, 962.3, or 250.8 modified by 259.8, 272.7, 681, 682, 686.9, 707.1-707.9, 709.3, 730.0-730.2, or 731.8).¹⁶

The secondary outcome was the change in hemoglobin A_{1c} level, which is a marker for the clinical effectiveness of insulin. For the baseline hemoglobin A_{1c} level, the last measure during the 12 months prior to insulin initiation was used. The change from baseline to the last hemoglobin A_{1c} level was

assessed prior to censoring and within 3 to 12 months after insulin initiation. A change in hemoglobin A_{1c} level of 0.5% or greater is typically considered to be clinically significant.¹⁷

Statistical Analysis

The analysis involved multiple steps. During the first step, a propensity score model was developed, predicting the binary outcome of initiating treatment with basal insulin analogs (compared with NPH insulin) using a flexible, data-adaptive model selection procedure called the deletion, substitution, and addition algorithm by Neugebauer and Bullard (available in R version 3.1.4; R Foundation for Statistical Computing).¹⁸ The deletion, substitution, and addition procedure made use of training and test data sets to select the estimator with the lowest cross-validated risk among a list of candidate estimators developed via machine learning (ie, deletion, substitution, and addition of potential covariates as well as interactions and higher-order parameters).


Potential covariates included: demographics, index year, clinical and comorbid characteristics, clinician specialty (primary care, endocrinology, or other specialty), KPNC service area, Charlson comorbidity index, chronic kidney disease stage, chronic liver disease, visual impairment, history of diabetic ketoacidosis, history of depression, glycemic control, the number of hypoglycemia-related ED visits or hospital admissions during the year prior to baseline, the number of ED visits or inpatient stays (for any reason) during the year prior to baseline, medication nonadherence (continuous measure of medication gaps^{19,20}), outpatient medical visits (ie, the number of face-to-face visits with a clinician) during the 2 years prior to baseline, the patient co-pay for index insulin dispensed, and indicators of prevalent use for each of the diabetes therapeutic drug classes, statins, angiotensin-converting enzyme inhibitors, and β -blockers.

Missing data for continuous variables were imputed based on the within-group mean. Missing data for categorical variables were treated as a separate category. The C statistic (area under the receiver operating characteristic curve) for this model was 0.81, suggesting good discrimination.

During the second step, the predicted probability (ie, propensity score) of initiating treatment with long-acting insulin analogs was calculated for each patient. Quintiles of the propensity score were created based on the distribution of the propensity scores among the exposed patients (ie, patients who initiated insulin analogs). Using frequency matching (random sampling with replacement), 500 reference patients who initiated NPH insulin were selected from each of the quintiles defined by the exposed group.

This frequency matching created a population in which the distribution of covariates in the NPH insulin cohort was similar to those in the insulin analog cohort, thus minimizing observed confounders. Balance in the covariate distribution in each cohort was assessed by visually inspecting box plots and cumulative probability distributions of the propensity scores between exposed and reference patients and quantitatively through the calculation of the standardized difference, which compares the difference in means or prevalence of baseline covariates in units of the pooled SDs. A standardized difference

Figure 1. Derivation of the Study Cohort



Adults with type 2 diabetes and full health plan and prescription coverage were included if they began basal insulin therapy (neutral protamine Hagedorn [NPH] or insulin analog) between January 1, 2006, and December 31, 2014.

with the absolute value of less than or equal to 0.1 indicates a negligible difference in the mean or prevalence of a covariate between groups.²¹

During the third step, a survival analysis was conducted for the outcome of hypoglycemia-related ED visits or hospital admissions. This approach examined time to first event of hypoglycemia-related ED visit or hospital admission. Patients were censored at the earliest event: death, end of KPNC membership, end of prescription drug benefits, discontinuation of NPH insulin or long-acting insulin, addition of any other insulin subtype, or end of follow-up (September 30, 2015). The hazard ratios (HRs) and 95% CIs were calculated from the results of the Cox proportional hazards analyses on 1000 bootstrap samples with replacement, and were created using the methods described above.

The proportional hazard assumption was tested by assessing independence between the Schoenfeld residuals and follow-up time. The primary analysis included the HR after adjusting for baseline covariates that remained unbalanced after propensity score matching (ie, those with the absolute value of the standardized difference >0.1), as well as additional adjustments for prior hypoglycemia-related ED visits or hospital admissions and for time-dependent indicators of diabetes medication use. The use of sulfonylureas, metformin, or thiazolidinediones was based on dispensing of a given medication within 6 months prior to the start of insulin; thereafter, it was based on monthly fills and days' supply dispensed.

In a sensitivity analysis, the HR was additionally calculated using traditional regression adjustment for covariates that were significantly different at baseline for prior hypoglycemia-related ED visits or hospital admissions and for time-dependent indicators of diabetes medication use. Based on a post hoc estimate with a sample size of 25 489 patients, the study had 80% power to detect a HR of 2.1 or greater or of 0.5 or less for the outcome of hypoglycemia-related ED visits or hospital admissions associated with the initiation of insulin analogs vs NPH insulin.

During the fourth step, the change in hemoglobin A_{1c} level following insulin initiation was estimated using a difference-in-differences approach. This approach measured the change

in glycemic control associated with the initiation of long-acting insulin analogs (first difference) after subtracting the background change (second difference [eg, due to secular trends]) among patients who initiated NPH insulin.²² This model was based on the counterfactual assumption that if patients who initiated insulin analogs had instead initiated NPH insulin, their changes in hemoglobin A_{1c} level would be similar to the changes observed in the NPH insulin reference group, who were frequency matched based on the propensity score quintile. The model was adjusted for baseline covariates that remained unbalanced after propensity score matching.

In the main secondary outcome analysis, participants with missing data for hemoglobin A_{1c} level at baseline and those who were censored within 90 days of baseline were excluded. In a sensitivity analysis, patients also were excluded if the use of any class of diabetes medications changed from baseline until they were censored or until 12 months after initiation of insulin, whichever occurred first. The purpose of this analysis was to isolate the relationship between insulin initiation and change in hemoglobin A_{1c} levels.

The difference-in-differences estimates and 95% CIs were calculated from the results of a least-squares regression analysis on 1000 bootstrap samples with replacement.²³ We used R version 3.3.1 and SAS version 9.3 (SAS Institute Inc) statistical software for all analyses. A *P* value < .05 was considered statistically significant and all testing was 2-sided.

Results

Patient Characteristics at Baseline

Between 2006 and 2014, a total of 25 489 patients with type 2 diabetes initiated basal insulin therapy (Table 1). The mean age was 60.2 years (SD, 11.8 years) and 46.8% were female. The racial/ethnic makeup of the cohort consisted of 51.9% who were white, 9.2% who were black, 17.6% who were Hispanic, and 15.3% who were Asian. The Charlson comorbidity index value was 0 among 28.1%, 1 among 28.5%, 2 among 11.3%, and 3 or greater among 32.1%.

In this cohort, data were missing for race/ethnicity (n = 280), chronic kidney disease stage (n = 213), duration of diabetes (n = 6641), age at diabetes onset (n = 6641), body mass index (n = 1429), elevated serum creatinine level (n = 33), neighborhood deprivation index (n = 242), hemoglobin A_{1c} level (n = 402), KPNC service area (n = 61), and medication non-adherence (n = 5474).

Among the patients who initiated insulin, 23 561 (92%) started with NPH insulin and 1928 (8%) started with insulin analogs. Patients who initiated insulin analogs were more likely to have a greater number of comorbid conditions and had more ED or hospital use events (for any cause) within the prior year, but the magnitude of the differences was small (Table 1). One substantive difference was that the median co-payments for insulin analogs (\$20) were significantly higher than for NPH insulin (\$10). The mean baseline hemoglobin A_{1c} levels for the 2 groups were 9.41% [SD, 2.0%] among patients who started insulin analogs and 9.40% [SD, 1.8%] among patients who started NPH insulin.

In the propensity score-matched cohort (n = 4428), the differences in the characteristics of patients who initiated insulin analog vs NPH insulin were minimized; however, statistical differences persisted for outpatient medical visits, KPNC service area, and year of index prescription. These differences were not substantive.

Primary Outcome

Among patients who initiated insulin analogs (n = 1928; 3289.8 person-years), there were 32 ED visits and 7 hospital admissions related to hypoglycemia (11.9 events [95% CI, 8.1 to 15.6] per 1000 person-years) during a mean follow-up of 1.71 years (95% CI, 1.62 to 1.79) and a median follow-up of 1.03 years (interquartile range, 0.36 to 2.37). Among patients who initiated NPH insulin (n = 23 561; 40 060.0 person-years), there were 309 ED visits and 45 hospital admissions related to hypoglycemia (8.8 events [95% CI, 7.9 to 9.8] per 1000 person-years) during a mean follow-up of 1.70 years (95% CI, 1.68 to 1.72) and a median follow-up of 1.09 years (interquartile range, 0.41 to 2.38). The between-group difference was 3.1 events (95% CI, -1.5 to 7.7) per 1000 person-years (*P* = .07).

The Kaplan-Meier curve appears in Figure 2. Among all censoring events, 2.8% were due to death, 31.9% were due to discontinuation of insulin, and 31.6% were due to initiation of an additional type of insulin. The proportional hazard assumption was met because the Schoenfeld residuals for the exposure were independent of time (Pearson correlation coefficient, 0.06; *P* = .20).

After frequency matching the patients who initiated insulin analogs with those who initiated NPH insulin, and after additional adjustment for unbalanced covariates, prior hypoglycemia-related ED visits or hospital admissions, and time-dependent indicators of diabetes medication use, there was no significant difference in hypoglycemia-related ED visits or hospital admissions (HR, 1.16 [95% CI, 0.71 to 1.78]; Table 2).

Secondary Outcome

In the main secondary outcome analysis of change in glycemic control, participants with missing data for hemoglobin A_{1c} level at baseline (n = 402) and those who were censored within 90 days of baseline (n = 3665) were excluded (n = 4067). Within 1 year of initiation of insulin analogs, hemoglobin A_{1c} level decreased by 1.26 percentage points (95% CI, 1.16 to 1.36 percentage points) from 9.41% (95% CI, 9.34% to 9.50%) to 8.16% (95% CI, 8.09% to 8.24%).

Within 1 year of initiation of NPH insulin, hemoglobin A_{1c} level decreased by 1.48 percentage points (95% CI, 1.39 to 1.57 percentage points) from 9.39% (95% CI, 9.32% to 9.47%) to 7.92% (95% CI, 7.85% to 7.99%). Between the baseline and post-baseline measures, the mean number of days was 298 (SD, 103 days) among patients who initiated insulin analogs and 288 days (SD, 98 days) among patients who initiated NPH (standardized difference, 0.10). After adjustment, the difference-in-differences for glycemic control was -0.22% (95% CI, -0.09% to -0.37%), indicating that the use of NPH insulin was associated with a statistically significant greater decrease in hemoglobin A_{1c} level (Table 3). However, this difference is not considered clinically significant.¹⁷

Table 1. Baseline Characteristics of 25 489 Patients With Type 2 Diabetes

Characteristic	Insulin Analog (n = 1928)	Before Frequency Matching		After Frequency Matching ^a	
		NPH Insulin (n = 23 561)	Standardized Difference ^b	NPH Insulin (n = 2500) ^c	Standardized Difference ^b
Age, mean (SD), y	60.6 (12.8)	60.2 (11.8)	0.04	60.8 (11.8)	-0.01
Female sex, No. (%)	912 (47)	11 105 (47)	0.01	1140 (46)	0.03
Race/ethnicity, No. (%) ^d					
Asian	332 (17)	3534 (15)	0.06	383 (15)	0.05
Black	214 (11)	2109 (9)	0.07	231 (9)	0.06
White	957 (50)	12 136 (52)	-0.04	1265 (51)	-0.02
Hispanic	293 (15)	4130 (18)	-0.06	446 (18)	-0.07
Other	114 (6)	1390 (6)	-0.04	133 (5)	-0.04
Neighborhood deprivation index by quartile, No. (%) ^{d,e}					
First (least deprived)	374 (20)	4643 (20)	-0.01	486 (19)	-0.002
Second	538 (28)	6695 (29)	-0.01	702 (28)	-0.004
Third	572 (30)	7030 (30)	-0.004	760 (30)	-0.02
Fourth (most deprived)	423 (22)	4972 (21)	0.02	532 (21)	0.02
Comorbidities, No. (%)					
Charlson comorbidity index ^f					
0	501 (26)	6654 (28)	-0.05	690 (28)	-0.04
1	533 (28)	6736 (29)	-0.02	735 (29)	-0.04
2	228 (12)	2652 (11)	0.02	256 (10)	0.05
≥3	666 (35)	7519 (32)	0.06	819 (33)	0.04
Chronic kidney disease stage ^d					
0	202 (11)	3121 (13)	-0.09	337 (14)	-0.09
1	468 (25)	6024 (26)	-0.03	597 (24)	0.01
2	656 (35)	8348 (36)	-0.03	883 (35)	-0.03
3A	297 (15)	3064 (13)	0.04	316 (13)	0.05
3B	179 (9)	2088 (9)	0.01	237 (9)	-0.01
4	77 (4)	627 (3)	0.07	82 (3)	0.04
5 or dialysis	28 (1)	115 (1)	0.10	19 (1)	0.07
Elevated serum creatinine level, No. ^{d,g}	266 (14)	2664 (11)	0.08	334 (13)	0.01
Chronic liver disease	103 (5)	1392 (6)	-0.02	141 (6)	-0.01
Depression	395 (20)	5266 (22)	-0.05	527 (21)	-0.01
Visual impairment or blindness	95 (5)	618 (3)	0.12	93 (4)	0.06
Health Care Use, No. (%)					
Emergency department visit for any cause in prior year	649 (34)	6822 (29)	0.10	780 (31)	0.05
Inpatient hospitalization for any cause in prior year	379 (20)	3069 (13)	0.18	421 (17)	0.07
No. of outpatient medical visits in prior 2 y by quartile					
0-6	423 (22)	5931 (25)	-0.08	613 (25)	-0.06
7-11	435 (23)	6148 (26)	-0.08	609 (24)	-0.04
12-19	480 (25)	5769 (24)	0.01	631 (25)	-0.01
≥20	590 (31)	5713 (24)	-0.14	647 (26)	0.11
Diabetic ketoacidosis in prior year	31 (2)	206 (1)	0.07	46 (2)	-0.02
Emergency department or inpatient hospitalization for hypoglycemia within prior year	16 (1)	115 (1)	0.04	22 (1)	-0.01
No. of hypoglycemic events resulting in emergency department or inpatient stay in prior year, median (IQR)	0 (0 to 2)	0 (0 to 3)	0.04	0 (0 to 3)	-0.0002
Kaiser Permanente of Northern California service area ^d					
A	114 (6)	1939 (8)	-0.10	196 (8)	-0.08
B	209 (11)	2392 (10)	0.02	224 (9)	0.06
C	123 (6)	1631 (7)	-0.02	121 (5)	0.07
D	144 (7)	740 (3)	0.19	172 (7)	0.02
E	128 (7)	1870 (8)	-0.05	164 (7)	0.004
F	71 (4)	1513 (6)	-0.13	123 (5)	-0.06
G	253 (13)	2080 (9)	-0.14	272 (11)	0.07
H	139 (7)	3810 (16)	-0.28	244 (10)	-0.09
I	97 (5)	1981 (8)	-0.14	166 (7)	-0.07
J	143 (7)	581 (2)	0.23	135 (5)	0.08
K	65 (3)	1831 (8)	-0.19	175 (7)	-0.16
L	139 (7)	1600 (7)	0.02	129 (5)	0.09
M	272 (14)	1513 (6)	0.26	354 (14)	-0.001

(continued)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.